Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancerButter, R., 't Hart, N. A., Hooijer, G. K. J., Monkhorst, K., Speel, E-J., Theunissen, P., Thunnissen, E., Von der Thüsen, J. H., Timens, W. & van de Vijver, M. J., Jul-2020, In : Journal of Clinical Pathology. 73, 7, p. 423-430 8 p.
Research output: Contribution to journal › Article › Academic › peer-review
Aims Investigate the impact of interlaboratory- and interobserver variability of immunohistochemistry on the assessment of programmed death ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC). Methods Two tissue microarrays (TMAs) were constructed from 50 (TMA-A) and 51 (TMA-B) resected NSCLC cases, and distributed among eight centres. Immunostaining for PD-L1 was performed using Agilent's 22C3 pharmDx Assay (pharmDx) and/or a 22C3 laboratory developed test (LDT). The interlaboratory variability of staining- and interobserver variability of scoring for PD-L1 were assessed in selected critical samples (samples at the cut-off of positivity) and non-critical samples. Also, PD-L1 epitope deterioration in time in stored unstained slides was analysed. Krippendorff's alpha values (0=maximal, 1=no variability) were calculated as measure for variability. Results For interlaboratory variability of immunostaining, the percentage of PD-L1 positive cases among centres ranged 40%-51% (1% cut-off) and 23%-30% (50% cut-off). Alpha values at 1% cut-off were 0.88 (pharmDx) and 0.87 (LDT) and at 50% cut-off 0.82 (pharmDx) and 0.95 (LDT). Interobserver variability of scoring resulted in PD-L1 positive cases ranging 29%-55% (1% cut-off) and 14%-30% (50% cut-off) among pathologists. Alpha values were at 1% cut-off 0.83 (TMA-A) and 0.66 (TMA-B), and at 50% cut-off 0.77 (TMA-A) and 0.78 (TMA-B). Interlaboratory variability of staining was higher (p
|Number of pages||8|
|Journal||Journal of Clinical Pathology|
|Early online date||10-Dec-2019|
|Publication status||Published - Jul-2020|
- lung cancer, immunohistochemistry, oncology, pulmonary pathology, histopathology, SQUAMOUS-CELL, OPEN-LABEL, EXPRESSION, DOCETAXEL, PEMBROLIZUMAB, BLOCKADE, ASSAY, HETEROGENEITY, ATEZOLIZUMAB, NIVOLUMAB